v3.26.1
Revenue (Tables)
3 Months Ended
Mar. 31, 2026
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregated Revenue

The following table presents our disaggregated revenue for the periods presented (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

2026

 

 

2025

 

MRD revenue

 

 

 

 

 

 

Service revenue

 

$

58,093

 

 

$

39,221

 

Regulatory milestone revenue

 

 

9,000

 

 

 

4,500

 

Total MRD revenue

 

 

67,093

 

 

 

43,721

 

Immune Medicine revenue

 

 

 

 

 

 

Service and licensing revenue

 

 

3,781

 

 

 

5,122

 

Collaboration revenue(1)

 

 

 

 

 

3,600

 

Total Immune Medicine revenue

 

 

3,781

 

 

 

8,722

 

Total revenue

 

$

70,874

 

 

$

52,443

 

(1) On August 13, 2025, the Genentech Agreement was terminated, with termination effective February 9, 2026.